ESMO 2024: Treatment of uHCC - Episode 9

ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

November 8, 2024

Richard Finn, MD, Olatunji Alese, MD, Daneng Li, MD, Anthony El-Khoueiry, MD, Masatoshi Kudo, MD, PhD, Steven Chan, MD

Panelists discuss findings from the IMmbrave050 trial comparing atezolizumab plus bevacizumab to active surveillance in patients with high-risk hepatocellular carcinoma patients, highlighting the significance of follow-up for those at risk of recurrence post- curative treatment.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP. 2: Treatment Decisions Based on BLCL Stage

EP. 3: Current Treatment in First Line – IO + TKI or IO + IO

EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line

EP. 5: EMERALD-1 Study Results

EP. 6: Discussion and Summary

EP. 7: LEAP-012 Study Results

EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

Now Viewing

EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received

EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP. 12: CELESTIAL Sub-Group Discussion

EP. 13: Discussion of RESORCE Trial

EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial

Video content above is prompted by the following:

Dr Li: Please discuss the IMmBRAVEbrave050 trial evaluating atezolizumab +plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinomaHCC. (Yopp A, ESMO Congress 2024, LBA39).
• Please comment on:
o• the Iimportance or non-importance of follow-up for patients who are at high risk of recurrence after receiving curative-intent resection or ablation with curative intent.